data_1go1_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1go1 _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' -2' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.526 0 CA-C-O 119.852 -0.415 . . . . 7.8300000000000001 112.866 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 17.8 t 52.99 42.18 32.22 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 123.892 0.877 . . . . 6.8799999999999999 112.342 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 17.2 m -60.74 116.37 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.023 0 CA-C-N 116.118 -0.492 . . . . 4.0800000000000001 110.728 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -61.33 -49.94 74.95 Favored 'General case' 0 N--CA 1.481 1.078 0 CA-C-O 119.128 -0.463 . . . . 2.6600000000000001 111.549 -178.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 67.1 t80 73.33 -47.19 0.66 Allowed 'General case' 0 N--CA 1.493 1.697 0 C-N-CA 124.358 1.063 . . . . 1.6299999999999999 113.013 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -56.69 -50.7 71.37 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 123.683 0.793 . . . . 1.29 112.56 -179.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 46.3 t80 -61.73 -38.94 89.78 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 123.148 0.579 . . . . 2.0299999999999998 111.039 178.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -65.17 -39.86 93.52 Favored 'General case' 0 N--CA 1.482 1.147 0 C-N-CA 123.143 0.577 . . . . 2.0899999999999999 111.525 178.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 10.8 mt -68.4 -48.24 65.19 Favored 'General case' 0 N--CA 1.489 1.499 0 CA-C-O 119.323 -0.37 . . . . 2.1600000000000001 111.449 179.379 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 7.5 ptp180 -65.14 -37.22 86.7 Favored 'General case' 0 N--CA 1.493 1.701 0 CA-C-N 117.773 0.26 . . . . 4.3499999999999996 111.642 179.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.4 mmpt? -69.77 -37.63 76.44 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 122.559 0.344 . . . . 3.4100000000000001 110.632 177.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -69.64 -37.01 76.6 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 122.943 0.497 . . . . 1.1399999999999999 112.093 178.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 32.8 tt0 -76.3 -33.06 59.06 Favored 'General case' 0 N--CA 1.489 1.479 0 C-N-CA 122.856 0.462 . . . . 3.0600000000000001 112.093 179.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -79.83 -48.05 14.16 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 122.922 0.489 . . . . 1.4299999999999999 111.908 -179.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.2 m -84.83 -54.27 4.79 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 122.911 0.484 . . . . 2.4100000000000001 111.894 -179.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -91.47 -133.66 5.95 Favored Glycine 0 C--N 1.357 1.71 0 CA-C-O 119.693 -0.504 . . . . 0.92000000000000004 113.354 -179.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 12.5 ttmm -144.4 135.98 25.74 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 122.779 0.431 . . . . 3.98 111.419 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.6 mm -129.36 126.68 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 123.211 0.605 . . . . 1.6599999999999999 109.575 179.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 38.1 t -106.03 95.72 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 N-CA-C 108.866 -0.79 . . . . 1.5700000000000001 108.866 179.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 2.5 ptp -84.18 130.81 34.81 Favored 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 122.59 0.356 . . . . 2.5499999999999998 111.609 -179.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 148.3 144.05 3.91 Favored Glycine 0 C--N 1.355 1.597 0 O-C-N 123.488 0.493 . . . . 1.71 112.377 -179.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.05 -47.3 45.99 Favored 'General case' 0 N--CA 1.487 1.38 0 CA-C-N 117.064 0.432 . . . . 1.5 111.969 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.8 ttp-105 -72.12 -36.28 69.38 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 123.176 0.59 . . . . 5.4500000000000002 112.143 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 91.4 mttt -68.74 -32.07 71.58 Favored 'General case' 0 N--CA 1.488 1.463 0 C-N-CA 122.561 0.345 . . . . 2.5299999999999998 111.811 179.245 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 29.9 m -65.64 -31.52 72.6 Favored 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 122.637 0.375 . . . . 1.6200000000000001 111.752 178.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 29.5 mt -73.53 -42.11 55.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 C-N-CA 123.007 0.523 . . . . 1.3200000000000001 110.159 178.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 19.1 tt0 -61.52 -41.33 97.17 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 123.079 0.552 . . . . 2.25 111.68 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -70.44 -32.6 70.25 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 122.6 0.36 . . . . 1.21 110.921 178.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -73.66 -31.29 63.4 Favored 'General case' 0 N--CA 1.483 1.213 0 C-N-CA 122.787 0.435 . . . . 1.1100000000000001 111.528 177.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 82.5 mttt -63.55 -53.61 49.07 Favored 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 123.352 0.661 . . . . 2.5699999999999998 111.84 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' MET . . . . . . . . . . . . . 22.8 ptp -79.47 -37.58 36.51 Favored 'General case' 0 N--CA 1.487 1.416 0 N-CA-C 112.837 0.68 . . . . 3.6600000000000001 112.837 -179.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.49 56.38 1.11 Allowed Glycine 0 C--N 1.357 1.71 0 CA-C-O 119.6 -0.556 . . . . 1.8899999999999999 113.341 179.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -126.06 41.64 1.62 Allowed Glycine 0 C--N 1.355 1.61 0 CA-C-O 119.687 -0.507 . . . . 1.6699999999999999 112.784 179.401 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -139.97 143.32 36.47 Favored 'General case' 0 C--N 1.358 0.965 0 C-N-CA 123.075 0.55 . . . . 1.22 111.27 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 15.6 mmtm -84.25 -51.26 7.15 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 122.971 0.508 . . . . 2.52 110.733 179.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 17.9 tp -140.88 131.43 25.44 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 122.797 0.439 . . . . 1.72 110.578 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 61.3 mt -112.73 116.7 53.35 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 N-CA-C 109.756 -0.461 . . . . 1.0800000000000001 109.756 179.106 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 48.8 mt -98.5 128.03 50.43 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 109.584 -0.525 . . . . 1.1499999999999999 109.584 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 19.9 m -118.98 136.09 57.3 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 C-N-CA 122.959 0.504 . . . . 1.1399999999999999 111.027 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -77.74 130.63 36.99 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 122.539 0.336 . . . . 1.1499999999999999 110.86 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 13.7 ptp180 -63.2 -29.54 70.86 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 112.952 0.723 . . . . 4.7000000000000002 112.952 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -82.81 -1.82 52.84 Favored 'General case' 0 CA--C 1.562 1.428 0 N-CA-C 112.716 0.635 . . . . 2.9900000000000002 112.716 179.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -73.71 175.2 7.4 Favored 'General case' 0 C--N 1.368 1.394 0 C-N-CA 122.964 0.506 . . . . 1.1499999999999999 111.336 179.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -63.83 145.01 97.93 Favored Pre-proline 0 N--CA 1.489 1.491 0 CA-C-O 119.231 -0.414 . . . . 4.6699999999999999 112.074 -179.46 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -64.17 -39.32 31.47 Favored 'Trans proline' 0 C--N 1.389 2.677 0 C-N-CA 122.83 2.353 . . . . 0.85999999999999999 113.247 179.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -67.06 -31.6 72.21 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 112.078 0.399 . . . . 2.48 112.078 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 48.6 mm -72.94 -46.51 51.87 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 122.747 0.419 . . . . 1.3 110.07 178.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -66.37 -43.49 85.78 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 122.978 0.511 . . . . 2.0699999999999998 111.949 179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -69.24 -36.06 76.77 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 112.57 0.582 . . . . 2.6000000000000001 112.57 -179.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -69.67 -46.11 66.82 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-N 117.938 0.335 . . . . 1.21 110.807 179.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 55.4 mt -66.05 -42.12 90.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 C-N-CA 122.572 0.349 . . . . 1.03 110.692 178.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -67.05 -44.52 79.96 Favored 'General case' 0 N--CA 1.487 1.418 0 CA-C-O 119.355 -0.355 . . . . 1.6699999999999999 111.827 179.438 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 80.0 t80 -65.28 -45.49 84.25 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 122.781 0.432 . . . . 1.3799999999999999 111.457 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 13.1 m-85 -70.32 -34.86 73.19 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 122.736 0.414 . . . . 1.5700000000000001 111.912 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -75.19 -31.59 60.98 Favored 'General case' 0 N--CA 1.485 1.301 0 C-N-CA 122.639 0.376 . . . . 1.0600000000000001 111.877 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.02 -51.09 68.13 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 123.033 0.533 . . . . 4.79 112.269 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.6 pp -70.67 -34.09 71.63 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 113.319 0.859 . . . . 1.98 113.319 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 77.8 p -72.37 -37.44 68.78 Favored 'General case' 0 N--CA 1.489 1.506 0 CA-C-N 118.064 0.393 . . . . 1.6399999999999999 112.047 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 110.9 42.13 1.13 Allowed Glycine 0 C--N 1.361 1.954 0 CA-C-O 119.401 -0.666 . . . . 0.83999999999999997 113.822 179.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 31.5 mt -124.98 117.86 25.73 Favored Pre-proline 0 CA--C 1.556 1.188 0 N-CA-C 109.274 -0.639 . . . . 1.1299999999999999 109.274 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -65.74 142.13 68.8 Favored 'Trans proline' 0 C--N 1.386 2.526 0 C-N-CA 122.382 2.054 . . . . 0.46000000000000002 113.216 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 3.4 t -112.39 138.52 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 CA-C-N 116.038 -0.528 . . . . 1.0600000000000001 109.962 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 60.6 t80 -119.17 116.58 26.62 Favored 'General case' 0 C--N 1.352 0.679 0 O-C-N 123.466 0.479 . . . . 1.1299999999999999 110.511 178.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -75.43 112.06 11.35 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.475 -0.565 . . . . 2.4700000000000002 109.475 177.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -67.77 131.42 45.52 Favored 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 123.284 0.634 . . . . 0.91000000000000003 111.091 -179.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -86.59 75.24 9.73 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 122.816 0.446 . . . . 2.46 110.319 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 178.06 -136.51 3.02 Favored Glycine 0 C--N 1.351 1.413 0 CA-C-N 115.929 -0.578 . . . . 0.81999999999999995 113.105 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 82.3 p -137.98 166.11 24.88 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 122.819 0.448 . . . . 2.0899999999999999 111.309 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.1 p -64.15 -29.8 70.9 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 122.786 0.434 . . . . 1.6200000000000001 111.902 178.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 37.3 t -67.98 -47.39 79.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 C-N-CA 123.09 0.556 . . . . 1.52 109.71 178.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -66.87 -38.24 85.95 Favored 'General case' 0 N--CA 1.486 1.364 0 C-N-CA 122.831 0.452 . . . . 2.6499999999999999 111.147 178.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 24.9 tp -64.84 -43.85 91.7 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 122.581 0.353 . . . . 1.21 110.871 178.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -65.68 -47.94 71.99 Favored Glycine 0 C--N 1.364 2.137 0 CA-C-O 119.76 -0.467 . . . . 0.83999999999999997 112.432 178.267 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 37.1 m -61.67 -36.08 79.83 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 123.039 0.535 . . . . 1.8100000000000001 110.998 177.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 49.7 tp -69.81 -42.56 73.52 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 123.217 0.607 . . . . 2.0699999999999998 111.918 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 13.9 mt -67.83 -28.07 67.25 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 112.194 0.442 . . . . 2.4399999999999999 112.194 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 113.86 -3.81 24.3 Favored Glycine 0 C--N 1.361 1.946 0 CA-C-O 119.35 -0.695 . . . . 2.2200000000000002 113.314 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -92.97 136.78 24.28 Favored Pre-proline 0 C--N 1.363 1.163 0 CA-C-N 117.678 0.739 . . . . 4.8600000000000003 110.272 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -76.36 -6.41 17.11 Favored 'Trans proline' 0 C--N 1.383 2.362 0 C-N-CA 121.953 1.768 . . . . 1.9099999999999999 113.641 178.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 24.1 m-70 -91.2 159.36 16.1 Favored 'General case' 0 C--N 1.363 1.154 0 C-N-CA 123.504 0.721 . . . . 3.8999999999999999 110.487 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 46.8 p -80.29 113.67 18.64 Favored 'General case' 0 N--CA 1.481 1.103 0 C-N-CA 122.441 0.297 . . . . 1.75 110.668 179.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 54.9 t -89.73 119.74 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 N-CA-C 109.743 -0.466 . . . . 1.9299999999999999 109.743 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 38.1 m -86.55 -39.83 15.83 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 122.829 0.451 . . . . 1.6200000000000001 111.215 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -152.0 148.96 28.35 Favored 'General case' 0 C--N 1.36 1.024 0 C-N-CA 122.819 0.448 . . . . 1.1100000000000001 111.728 -179.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 3.2 pp -138.37 137.99 37.84 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 123.148 0.579 . . . . 1.6100000000000001 110.662 179.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -107.38 114.72 28.92 Favored 'General case' 0 C--N 1.355 0.818 0 C-N-CA 122.794 0.438 . . . . 1.01 111.056 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 23.2 t -86.24 107.41 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 N-CA-C 108.685 -0.857 . . . . 1.6599999999999999 108.685 179.062 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 40.2 t -80.93 -50.38 17.01 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 123.115 0.566 . . . . 1.27 110.875 -179.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -124.09 112.84 28.28 Favored Pre-proline 0 CA--C 1.555 1.138 0 CA-C-O 119.021 -0.514 . . . . 2.1499999999999999 110.756 -179.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -67.02 -47.16 2.57 Favored 'Trans proline' 0 C--N 1.389 2.665 0 C-N-CA 122.556 2.171 . . . . 1.6799999999999999 112.332 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 73.33 -118.05 6.1 Favored Glycine 0 C--N 1.361 1.961 0 O-C-N 123.336 0.398 . . . . 1.49 113.927 178.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -85.02 -32.73 22.77 Favored 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 123.224 0.61 . . . . 3.0299999999999998 112.315 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 99.3 p -65.02 147.55 53.28 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 112.948 0.721 . . . . 2.0699999999999998 112.948 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 20.3 mtp85 -97.4 55.63 1.28 Allowed 'General case' 0 N--CA 1.482 1.138 0 C-N-CA 123.196 0.598 . . . . 5.1900000000000004 109.613 178.516 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 5.3 tp -74.23 -31.02 27.96 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.241 0 C-N-CA 122.854 0.461 . . . . 1.4299999999999999 112.187 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 38.0 mt -66.15 -22.84 66.39 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 112.995 0.739 . . . . 2.1600000000000001 112.995 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -72.89 -22.47 60.75 Favored 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 112.72 0.637 . . . . 1.4399999999999999 112.72 179.329 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.8 mt -71.95 -33.89 68.56 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 112.761 0.652 . . . . 2.1699999999999999 112.761 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -174.43 40.74 0.13 Allowed Glycine 0 C--N 1.353 1.486 0 CA-C-O 119.62 -0.544 . . . . 1.79 113.79 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.79 58.45 0.56 Allowed Glycine 0 C--N 1.354 1.531 0 N-CA-C 111.43 -0.668 . . . . 2.8500000000000001 111.43 179.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.3 ttpp 67.39 149.74 0.06 Allowed 'General case' 0 N--CA 1.483 1.188 0 C-N-CA 124.124 0.97 . . . . 7.04 111.977 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.48 1.026 0 CA-C-O 118.11 -0.948 . . . . 7.0099999999999998 111.107 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' -2' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.526 0 CA-C-O 119.852 -0.415 . . . . 7.54 112.866 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 17.8 t 52.99 42.18 32.22 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 123.892 0.877 . . . . 6.58 112.342 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 17.2 m -60.74 116.37 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.023 0 CA-C-N 116.118 -0.492 . . . . 3.59 110.728 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -61.33 -49.94 74.95 Favored 'General case' 0 N--CA 1.481 1.078 0 CA-C-O 119.128 -0.463 . . . . 2.66 111.549 -178.602 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 67.1 t80 73.33 -47.19 0.66 Allowed 'General case' 0 N--CA 1.493 1.697 0 C-N-CA 124.358 1.063 . . . . 1.16 113.013 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.645 ' CB ' HD11 ' A' ' 73' ' ' LEU . . . -56.69 -50.7 71.37 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 123.683 0.793 . . . . 0.64 112.56 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 46.3 t80 -61.73 -38.94 89.78 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 123.148 0.579 . . . . 1.65 111.039 178.567 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -65.17 -39.86 93.52 Favored 'General case' 0 N--CA 1.482 1.147 0 C-N-CA 123.143 0.577 . . . . 2.09 111.525 178.704 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 10.8 mt -68.4 -48.24 65.19 Favored 'General case' 0 N--CA 1.489 1.499 0 CA-C-O 119.323 -0.37 . . . . 1.45 111.449 179.379 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 7.5 ptp180 -65.14 -37.22 86.7 Favored 'General case' 0 N--CA 1.493 1.701 0 CA-C-N 117.773 0.26 . . . . 3.56 111.642 179.532 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.4 mmpt? -69.77 -37.63 76.44 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 122.559 0.344 . . . . 2.75 110.632 177.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.488 ' HB1' HD11 ' A' ' 16' ' ' ILE . . . -69.64 -37.01 76.6 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 122.943 0.497 . . . . 0.47 112.093 178.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 32.8 tt0 -76.3 -33.06 59.06 Favored 'General case' 0 N--CA 1.489 1.479 0 C-N-CA 122.856 0.462 . . . . 2.44 112.093 179.641 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -79.83 -48.05 14.16 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 122.922 0.489 . . . . 1.43 111.908 -179.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.2 m -84.83 -54.27 4.79 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 122.911 0.484 . . . . 1.96 111.894 -179.296 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -91.47 -133.66 5.95 Favored Glycine 0 C--N 1.357 1.71 0 CA-C-O 119.693 -0.504 . . . . 0.64 113.354 -179.203 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 12.5 ttmm -144.4 135.98 25.74 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 122.779 0.431 . . . . 3.52 111.419 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.488 HD11 ' HB1' ' A' ' 10' ' ' ALA . 31.6 mm -129.36 126.68 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 123.211 0.605 . . . . 0.99 109.575 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 38.1 t -106.03 95.72 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 N-CA-C 108.866 -0.79 . . . . 1.04 108.866 179.333 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 2.5 ptp -84.18 130.81 34.81 Favored 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 122.59 0.356 . . . . 2.03 111.609 -179.223 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 148.3 144.05 3.91 Favored Glycine 0 C--N 1.355 1.597 0 O-C-N 123.488 0.493 . . . . 1.71 112.377 -179.724 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.05 -47.3 45.99 Favored 'General case' 0 N--CA 1.487 1.38 0 CA-C-N 117.064 0.432 . . . . 0.76 111.969 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.8 ttp-105 -72.12 -36.28 69.38 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 123.176 0.59 . . . . 4.68 112.143 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 91.4 mttt -68.74 -32.07 71.58 Favored 'General case' 0 N--CA 1.488 1.463 0 C-N-CA 122.561 0.345 . . . . 1.91 111.811 179.245 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 29.9 m -65.64 -31.52 72.6 Favored 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 122.637 0.375 . . . . 1.14 111.752 178.439 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 29.5 mt -73.53 -42.11 55.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 C-N-CA 123.007 0.523 . . . . 0.66 110.159 178.679 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 19.1 tt0 -61.52 -41.33 97.17 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 123.079 0.552 . . . . 2.19 111.68 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -70.44 -32.6 70.25 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 122.6 0.36 . . . . 0.66 110.921 178.456 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -73.66 -31.29 63.4 Favored 'General case' 0 N--CA 1.483 1.213 0 C-N-CA 122.787 0.435 . . . . 0.55 111.528 177.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 82.5 mttt -63.55 -53.61 49.07 Favored 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 123.352 0.661 . . . . 2.06 111.84 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' MET . . . . . . . . . . . . . 22.8 ptp -79.47 -37.58 36.51 Favored 'General case' 0 N--CA 1.487 1.416 0 N-CA-C 112.837 0.68 . . . . 3.09 112.837 -179.096 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.525 ' HA2' HD11 ' A' ' 58' ' ' ILE . . . 97.49 56.38 1.11 Allowed Glycine 0 C--N 1.357 1.71 0 CA-C-O 119.6 -0.556 . . . . 1.43 113.341 179.665 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -126.06 41.64 1.62 Allowed Glycine 0 C--N 1.355 1.61 0 CA-C-O 119.687 -0.507 . . . . 1.67 112.784 179.401 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -139.97 143.32 36.47 Favored 'General case' 0 C--N 1.358 0.965 0 C-N-CA 123.075 0.55 . . . . 0.55 111.27 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 15.6 mmtm -84.25 -51.26 7.15 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 122.971 0.508 . . . . 1.85 110.733 179.305 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 17.9 tp -140.88 131.43 25.44 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 122.797 0.439 . . . . 1.06 110.578 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 61.3 mt -112.73 116.7 53.35 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 N-CA-C 109.756 -0.461 . . . . 0.31 109.756 179.106 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.541 HD12 HD11 ' A' ' 83' ' ' LEU . 48.8 mt -98.5 128.03 50.43 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 109.584 -0.525 . . . . 0.4 109.584 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 19.9 m -118.98 136.09 57.3 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 C-N-CA 122.959 0.504 . . . . 0.34 111.027 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -77.74 130.63 36.99 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 122.539 0.336 . . . . 0.33 110.86 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 13.7 ptp180 -63.2 -29.54 70.86 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 112.952 0.723 . . . . 4.14 112.952 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -82.81 -1.82 52.84 Favored 'General case' 0 CA--C 1.562 1.428 0 N-CA-C 112.716 0.635 . . . . 2.33 112.716 179.434 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -73.71 175.2 7.4 Favored 'General case' 0 C--N 1.368 1.394 0 C-N-CA 122.964 0.506 . . . . 0.47 111.336 179.066 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -63.83 145.01 97.93 Favored Pre-proline 0 N--CA 1.489 1.491 0 CA-C-O 119.231 -0.414 . . . . 3.98 112.074 -179.46 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -64.17 -39.32 31.47 Favored 'Trans proline' 0 C--N 1.389 2.677 0 C-N-CA 122.83 2.353 . . . . 0.86 113.247 179.558 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -67.06 -31.6 72.21 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 112.078 0.399 . . . . 2.48 112.078 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 48.6 mm -72.94 -46.51 51.87 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 122.747 0.419 . . . . 0.62 110.07 178.413 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -66.37 -43.49 85.78 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 122.978 0.511 . . . . 1.59 111.949 179.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -69.24 -36.06 76.77 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 112.57 0.582 . . . . 2.6 112.57 -179.591 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -69.67 -46.11 66.82 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-N 117.938 0.335 . . . . 1.21 110.807 179.134 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 55.4 mt -66.05 -42.12 90.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 C-N-CA 122.572 0.349 . . . . 0.36 110.692 178.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -67.05 -44.52 79.96 Favored 'General case' 0 N--CA 1.487 1.418 0 CA-C-O 119.355 -0.355 . . . . 1.67 111.827 179.438 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 80.0 t80 -65.28 -45.49 84.25 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 122.781 0.432 . . . . 1.03 111.457 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 13.1 m-85 -70.32 -34.86 73.19 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 122.736 0.414 . . . . 1.09 111.912 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -75.19 -31.59 60.98 Favored 'General case' 0 N--CA 1.485 1.301 0 C-N-CA 122.639 0.376 . . . . 0.42 111.877 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.02 -51.09 68.13 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 123.033 0.533 . . . . 4.04 112.269 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.6 pp -70.67 -34.09 71.63 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 113.319 0.859 . . . . 1.37 113.319 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 77.8 p -72.37 -37.44 68.78 Favored 'General case' 0 N--CA 1.489 1.506 0 CA-C-N 118.064 0.393 . . . . 1.28 112.047 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 110.9 42.13 1.13 Allowed Glycine 0 C--N 1.361 1.954 0 CA-C-O 119.401 -0.666 . . . . 0.48 113.822 179.233 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.525 HD11 ' HA2' ' A' ' 30' ' ' GLY . 31.5 mt -124.98 117.86 25.73 Favored Pre-proline 0 CA--C 1.556 1.188 0 N-CA-C 109.274 -0.639 . . . . 0.36 109.274 179.389 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -65.74 142.13 68.8 Favored 'Trans proline' 0 C--N 1.386 2.526 0 C-N-CA 122.382 2.054 . . . . 0.46 113.216 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 3.4 t -112.39 138.52 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 CA-C-N 116.038 -0.528 . . . . 0.5 109.962 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 60.6 t80 -119.17 116.58 26.62 Favored 'General case' 0 C--N 1.352 0.679 0 O-C-N 123.466 0.479 . . . . 0.83 110.511 178.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -75.43 112.06 11.35 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.475 -0.565 . . . . 2.47 109.475 177.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -67.77 131.42 45.52 Favored 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 123.284 0.634 . . . . 0.67 111.091 -179.448 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -86.59 75.24 9.73 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 122.816 0.446 . . . . 2.46 110.319 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 178.06 -136.51 3.02 Favored Glycine 0 C--N 1.351 1.413 0 CA-C-N 115.929 -0.578 . . . . 0.82 113.105 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 82.3 p -137.98 166.11 24.88 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 122.819 0.448 . . . . 1.53 111.309 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.1 p -64.15 -29.8 70.9 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 122.786 0.434 . . . . 1.25 111.902 178.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 37.3 t -67.98 -47.39 79.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 C-N-CA 123.09 0.556 . . . . 0.97 109.71 178.17 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -66.87 -38.24 85.95 Favored 'General case' 0 N--CA 1.486 1.364 0 C-N-CA 122.831 0.452 . . . . 2.65 111.147 178.532 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 24.9 tp -64.84 -43.85 91.7 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 122.581 0.353 . . . . 0.56 110.871 178.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -65.68 -47.94 71.99 Favored Glycine 0 C--N 1.364 2.137 0 CA-C-O 119.76 -0.467 . . . . 0.84 112.432 178.267 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 37.1 m -61.67 -36.08 79.83 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 123.039 0.535 . . . . 1.46 110.998 177.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.645 HD11 ' CB ' ' A' ' 4' ' ' ALA . 49.7 tp -69.81 -42.56 73.52 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 123.217 0.607 . . . . 1.51 111.918 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 13.9 mt -67.83 -28.07 67.25 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 112.194 0.442 . . . . 1.79 112.194 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 113.86 -3.81 24.3 Favored Glycine 0 C--N 1.361 1.946 0 CA-C-O 119.35 -0.695 . . . . 2.22 113.314 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -92.97 136.78 24.28 Favored Pre-proline 0 C--N 1.363 1.163 0 CA-C-N 117.678 0.739 . . . . 4.36 110.272 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -76.36 -6.41 17.11 Favored 'Trans proline' 0 C--N 1.383 2.362 0 C-N-CA 121.953 1.768 . . . . 1.91 113.641 178.759 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 24.1 m-70 -91.2 159.36 16.1 Favored 'General case' 0 C--N 1.363 1.154 0 C-N-CA 123.504 0.721 . . . . 3.13 110.487 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 46.8 p -80.29 113.67 18.64 Favored 'General case' 0 N--CA 1.481 1.103 0 C-N-CA 122.441 0.297 . . . . 1.25 110.668 179.583 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 54.9 t -89.73 119.74 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 N-CA-C 109.743 -0.466 . . . . 1.24 109.743 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 38.1 m -86.55 -39.83 15.83 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 122.829 0.451 . . . . 1.18 111.215 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -152.0 148.96 28.35 Favored 'General case' 0 C--N 1.36 1.024 0 C-N-CA 122.819 0.448 . . . . 0.34 111.728 -179.702 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.541 HD11 HD12 ' A' ' 36' ' ' ILE . 3.2 pp -138.37 137.99 37.84 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 123.148 0.579 . . . . 0.88 110.662 179.443 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -107.38 114.72 28.92 Favored 'General case' 0 C--N 1.355 0.818 0 C-N-CA 122.794 0.438 . . . . 0.35 111.056 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.463 HG11 HG21 ' A' ' 93' ' ' ILE . 23.2 t -86.24 107.41 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 N-CA-C 108.685 -0.857 . . . . 1.05 108.685 179.062 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 40.2 t -80.93 -50.38 17.01 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 123.115 0.566 . . . . 0.54 110.875 -179.169 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -124.09 112.84 28.28 Favored Pre-proline 0 CA--C 1.555 1.138 0 CA-C-O 119.021 -0.514 . . . . 2.15 110.756 -179.477 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -67.02 -47.16 2.57 Favored 'Trans proline' 0 C--N 1.389 2.665 0 C-N-CA 122.556 2.171 . . . . 1.68 112.332 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 73.33 -118.05 6.1 Favored Glycine 0 C--N 1.361 1.961 0 O-C-N 123.336 0.398 . . . . 1.49 113.927 178.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -85.02 -32.73 22.77 Favored 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 123.224 0.61 . . . . 3.03 112.315 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 99.3 p -65.02 147.55 53.28 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 112.948 0.721 . . . . 1.65 112.948 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 20.3 mtp85 -97.4 55.63 1.28 Allowed 'General case' 0 N--CA 1.482 1.138 0 C-N-CA 123.196 0.598 . . . . 4.45 109.613 178.516 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.463 HG21 HG11 ' A' ' 85' ' ' VAL . 5.3 tp -74.23 -31.02 27.96 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.241 0 C-N-CA 122.854 0.461 . . . . 0.97 112.187 -179.538 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 38.0 mt -66.15 -22.84 66.39 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 112.995 0.739 . . . . 1.63 112.995 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -72.89 -22.47 60.75 Favored 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 112.72 0.637 . . . . 0.86 112.72 179.329 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.8 mt -71.95 -33.89 68.56 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 112.761 0.652 . . . . 1.57 112.761 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -174.43 40.74 0.13 Allowed Glycine 0 C--N 1.353 1.486 0 CA-C-O 119.62 -0.544 . . . . 1.79 113.79 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.79 58.45 0.56 Allowed Glycine 0 C--N 1.354 1.531 0 N-CA-C 111.43 -0.668 . . . . 2.85 111.43 179.091 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.3 ttpp 67.39 149.74 0.06 Allowed 'General case' 0 N--CA 1.483 1.188 0 C-N-CA 124.124 0.97 . . . . 6.7 111.977 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.48 1.026 0 CA-C-O 118.11 -0.948 . . . . 7.01 111.107 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' -2' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.526 0 CA-C-O 119.852 -0.415 . . . . 7.54 112.866 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 17.8 t 52.99 42.18 32.22 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 123.892 0.877 . . . . 6.58 112.342 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 17.2 m -60.74 116.37 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.023 0 CA-C-N 116.118 -0.492 . . . . 3.59 110.728 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -61.33 -49.94 74.95 Favored 'General case' 0 N--CA 1.481 1.078 0 CA-C-O 119.128 -0.463 . . . . 2.66 111.549 -178.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 67.1 t80 73.33 -47.19 0.66 Allowed 'General case' 0 N--CA 1.493 1.697 0 C-N-CA 124.358 1.063 . . . . 1.16 113.013 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.645 ' CB ' HD11 ' A' ' 73' ' ' LEU . . . -56.69 -50.7 71.37 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 123.683 0.793 . . . . 0.64 112.56 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 46.3 t80 -61.73 -38.94 89.78 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 123.148 0.579 . . . . 1.65 111.039 178.567 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -65.17 -39.86 93.52 Favored 'General case' 0 N--CA 1.482 1.147 0 C-N-CA 123.143 0.577 . . . . 2.09 111.525 178.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 10.8 mt -68.4 -48.24 65.19 Favored 'General case' 0 N--CA 1.489 1.499 0 CA-C-O 119.323 -0.37 . . . . 1.45 111.449 179.379 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 7.5 ptp180 -65.14 -37.22 86.7 Favored 'General case' 0 N--CA 1.493 1.701 0 CA-C-N 117.773 0.26 . . . . 3.56 111.642 179.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.4 mmpt? -69.77 -37.63 76.44 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 122.559 0.344 . . . . 2.75 110.632 177.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.488 ' HB1' HD11 ' A' ' 16' ' ' ILE . . . -69.64 -37.01 76.6 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 122.943 0.497 . . . . 0.47 112.093 178.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 32.8 tt0 -76.3 -33.06 59.06 Favored 'General case' 0 N--CA 1.489 1.479 0 C-N-CA 122.856 0.462 . . . . 2.44 112.093 179.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -79.83 -48.05 14.16 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 122.922 0.489 . . . . 1.43 111.908 -179.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.2 m -84.83 -54.27 4.79 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 122.911 0.484 . . . . 1.96 111.894 -179.296 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -91.47 -133.66 5.95 Favored Glycine 0 C--N 1.357 1.71 0 CA-C-O 119.693 -0.504 . . . . 0.64 113.354 -179.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 12.5 ttmm -144.4 135.98 25.74 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 122.779 0.431 . . . . 3.52 111.419 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.488 HD11 ' HB1' ' A' ' 10' ' ' ALA . 31.6 mm -129.36 126.68 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 123.211 0.605 . . . . 0.99 109.575 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 38.1 t -106.03 95.72 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 N-CA-C 108.866 -0.79 . . . . 1.04 108.866 179.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 2.5 ptp -84.18 130.81 34.81 Favored 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 122.59 0.356 . . . . 2.03 111.609 -179.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 148.3 144.05 3.91 Favored Glycine 0 C--N 1.355 1.597 0 O-C-N 123.488 0.493 . . . . 1.71 112.377 -179.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.05 -47.3 45.99 Favored 'General case' 0 N--CA 1.487 1.38 0 CA-C-N 117.064 0.432 . . . . 0.76 111.969 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.8 ttp-105 -72.12 -36.28 69.38 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 123.176 0.59 . . . . 4.68 112.143 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 91.4 mttt -68.74 -32.07 71.58 Favored 'General case' 0 N--CA 1.488 1.463 0 C-N-CA 122.561 0.345 . . . . 1.91 111.811 179.245 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 29.9 m -65.64 -31.52 72.6 Favored 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 122.637 0.375 . . . . 1.14 111.752 178.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 29.5 mt -73.53 -42.11 55.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 C-N-CA 123.007 0.523 . . . . 0.66 110.159 178.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 19.1 tt0 -61.52 -41.33 97.17 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 123.079 0.552 . . . . 2.19 111.68 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -70.44 -32.6 70.25 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 122.6 0.36 . . . . 0.66 110.921 178.456 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -73.66 -31.29 63.4 Favored 'General case' 0 N--CA 1.483 1.213 0 C-N-CA 122.787 0.435 . . . . 0.55 111.528 177.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 82.5 mttt -63.55 -53.61 49.07 Favored 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 123.352 0.661 . . . . 2.06 111.84 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' MET . . . . . . . . . . . . . 22.8 ptp -79.47 -37.58 36.51 Favored 'General case' 0 N--CA 1.487 1.416 0 N-CA-C 112.837 0.68 . . . . 3.09 112.837 -179.096 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.525 ' HA2' HD11 ' A' ' 58' ' ' ILE . . . 97.49 56.38 1.11 Allowed Glycine 0 C--N 1.357 1.71 0 CA-C-O 119.6 -0.556 . . . . 1.43 113.341 179.665 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -126.06 41.64 1.62 Allowed Glycine 0 C--N 1.355 1.61 0 CA-C-O 119.687 -0.507 . . . . 1.67 112.784 179.401 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -139.97 143.32 36.47 Favored 'General case' 0 C--N 1.358 0.965 0 C-N-CA 123.075 0.55 . . . . 0.55 111.27 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 15.6 mmtm -84.25 -51.26 7.15 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 122.971 0.508 . . . . 1.85 110.733 179.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 17.9 tp -140.88 131.43 25.44 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 122.797 0.439 . . . . 1.06 110.578 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 61.3 mt -112.73 116.7 53.35 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 N-CA-C 109.756 -0.461 . . . . 0.31 109.756 179.106 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.541 HD12 HD11 ' A' ' 83' ' ' LEU . 48.8 mt -98.5 128.03 50.43 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 109.584 -0.525 . . . . 0.4 109.584 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 19.9 m -118.98 136.09 57.3 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 C-N-CA 122.959 0.504 . . . . 0.34 111.027 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -77.74 130.63 36.99 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 122.539 0.336 . . . . 0.33 110.86 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 13.7 ptp180 -63.2 -29.54 70.86 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 112.952 0.723 . . . . 4.14 112.952 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -82.81 -1.82 52.84 Favored 'General case' 0 CA--C 1.562 1.428 0 N-CA-C 112.716 0.635 . . . . 2.33 112.716 179.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -73.71 175.2 7.4 Favored 'General case' 0 C--N 1.368 1.394 0 C-N-CA 122.964 0.506 . . . . 0.47 111.336 179.066 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -63.83 145.01 97.93 Favored Pre-proline 0 N--CA 1.489 1.491 0 CA-C-O 119.231 -0.414 . . . . 3.98 112.074 -179.46 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -64.17 -39.32 31.47 Favored 'Trans proline' 0 C--N 1.389 2.677 0 C-N-CA 122.83 2.353 . . . . 0.86 113.247 179.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -67.06 -31.6 72.21 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 112.078 0.399 . . . . 2.48 112.078 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 48.6 mm -72.94 -46.51 51.87 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 122.747 0.419 . . . . 0.62 110.07 178.413 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -66.37 -43.49 85.78 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 122.978 0.511 . . . . 1.59 111.949 179.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -69.24 -36.06 76.77 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 112.57 0.582 . . . . 2.6 112.57 -179.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -69.67 -46.11 66.82 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-N 117.938 0.335 . . . . 1.21 110.807 179.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 55.4 mt -66.05 -42.12 90.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 C-N-CA 122.572 0.349 . . . . 0.36 110.692 178.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -67.05 -44.52 79.96 Favored 'General case' 0 N--CA 1.487 1.418 0 CA-C-O 119.355 -0.355 . . . . 1.67 111.827 179.438 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 80.0 t80 -65.28 -45.49 84.25 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 122.781 0.432 . . . . 1.03 111.457 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 13.1 m-85 -70.32 -34.86 73.19 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 122.736 0.414 . . . . 1.09 111.912 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -75.19 -31.59 60.98 Favored 'General case' 0 N--CA 1.485 1.301 0 C-N-CA 122.639 0.376 . . . . 0.42 111.877 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.02 -51.09 68.13 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 123.033 0.533 . . . . 4.04 112.269 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.6 pp -70.67 -34.09 71.63 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 113.319 0.859 . . . . 1.37 113.319 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 77.8 p -72.37 -37.44 68.78 Favored 'General case' 0 N--CA 1.489 1.506 0 CA-C-N 118.064 0.393 . . . . 1.28 112.047 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 110.9 42.13 1.13 Allowed Glycine 0 C--N 1.361 1.954 0 CA-C-O 119.401 -0.666 . . . . 0.48 113.822 179.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.525 HD11 ' HA2' ' A' ' 30' ' ' GLY . 31.5 mt -124.98 117.86 25.73 Favored Pre-proline 0 CA--C 1.556 1.188 0 N-CA-C 109.274 -0.639 . . . . 0.36 109.274 179.389 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -65.74 142.13 68.8 Favored 'Trans proline' 0 C--N 1.386 2.526 0 C-N-CA 122.382 2.054 . . . . 0.46 113.216 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 3.4 t -112.39 138.52 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 CA-C-N 116.038 -0.528 . . . . 0.5 109.962 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 60.6 t80 -119.17 116.58 26.62 Favored 'General case' 0 C--N 1.352 0.679 0 O-C-N 123.466 0.479 . . . . 0.83 110.511 178.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -75.43 112.06 11.35 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.475 -0.565 . . . . 2.47 109.475 177.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -67.77 131.42 45.52 Favored 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 123.284 0.634 . . . . 0.67 111.091 -179.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -86.59 75.24 9.73 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 122.816 0.446 . . . . 2.46 110.319 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 178.06 -136.51 3.02 Favored Glycine 0 C--N 1.351 1.413 0 CA-C-N 115.929 -0.578 . . . . 0.82 113.105 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 82.3 p -137.98 166.11 24.88 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 122.819 0.448 . . . . 1.53 111.309 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.1 p -64.15 -29.8 70.9 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 122.786 0.434 . . . . 1.25 111.902 178.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 37.3 t -67.98 -47.39 79.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 C-N-CA 123.09 0.556 . . . . 0.97 109.71 178.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -66.87 -38.24 85.95 Favored 'General case' 0 N--CA 1.486 1.364 0 C-N-CA 122.831 0.452 . . . . 2.65 111.147 178.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 24.9 tp -64.84 -43.85 91.7 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 122.581 0.353 . . . . 0.56 110.871 178.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -65.68 -47.94 71.99 Favored Glycine 0 C--N 1.364 2.137 0 CA-C-O 119.76 -0.467 . . . . 0.84 112.432 178.267 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 37.1 m -61.67 -36.08 79.83 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 123.039 0.535 . . . . 1.46 110.998 177.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.645 HD11 ' CB ' ' A' ' 4' ' ' ALA . 49.7 tp -69.81 -42.56 73.52 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 123.217 0.607 . . . . 1.51 111.918 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 13.9 mt -67.83 -28.07 67.25 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 112.194 0.442 . . . . 1.79 112.194 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 113.86 -3.81 24.3 Favored Glycine 0 C--N 1.361 1.946 0 CA-C-O 119.35 -0.695 . . . . 2.22 113.314 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -92.97 136.78 24.28 Favored Pre-proline 0 C--N 1.363 1.163 0 CA-C-N 117.678 0.739 . . . . 4.36 110.272 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -76.36 -6.41 17.11 Favored 'Trans proline' 0 C--N 1.383 2.362 0 C-N-CA 121.953 1.768 . . . . 1.91 113.641 178.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 24.1 m-70 -91.2 159.36 16.1 Favored 'General case' 0 C--N 1.363 1.154 0 C-N-CA 123.504 0.721 . . . . 3.13 110.487 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 46.8 p -80.29 113.67 18.64 Favored 'General case' 0 N--CA 1.481 1.103 0 C-N-CA 122.441 0.297 . . . . 1.25 110.668 179.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 54.9 t -89.73 119.74 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 N-CA-C 109.743 -0.466 . . . . 1.24 109.743 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 38.1 m -86.55 -39.83 15.83 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 122.829 0.451 . . . . 1.18 111.215 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -152.0 148.96 28.35 Favored 'General case' 0 C--N 1.36 1.024 0 C-N-CA 122.819 0.448 . . . . 0.34 111.728 -179.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.541 HD11 HD12 ' A' ' 36' ' ' ILE . 3.2 pp -138.37 137.99 37.84 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 123.148 0.579 . . . . 0.88 110.662 179.443 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -107.38 114.72 28.92 Favored 'General case' 0 C--N 1.355 0.818 0 C-N-CA 122.794 0.438 . . . . 0.35 111.056 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.463 HG11 HG21 ' A' ' 93' ' ' ILE . 23.2 t -86.24 107.41 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 N-CA-C 108.685 -0.857 . . . . 1.05 108.685 179.062 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 40.2 t -80.93 -50.38 17.01 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 123.115 0.566 . . . . 0.54 110.875 -179.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -124.09 112.84 28.28 Favored Pre-proline 0 CA--C 1.555 1.138 0 CA-C-O 119.021 -0.514 . . . . 2.15 110.756 -179.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -67.02 -47.16 2.57 Favored 'Trans proline' 0 C--N 1.389 2.665 0 C-N-CA 122.556 2.171 . . . . 1.68 112.332 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 73.33 -118.05 6.1 Favored Glycine 0 C--N 1.361 1.961 0 O-C-N 123.336 0.398 . . . . 1.49 113.927 178.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -85.02 -32.73 22.77 Favored 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 123.224 0.61 . . . . 3.03 112.315 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 99.3 p -65.02 147.55 53.28 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 112.948 0.721 . . . . 1.65 112.948 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 20.3 mtp85 -97.4 55.63 1.28 Allowed 'General case' 0 N--CA 1.482 1.138 0 C-N-CA 123.196 0.598 . . . . 4.45 109.613 178.516 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.463 HG21 HG11 ' A' ' 85' ' ' VAL . 5.3 tp -74.23 -31.02 27.96 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.241 0 C-N-CA 122.854 0.461 . . . . 0.97 112.187 -179.538 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 38.0 mt -66.15 -22.84 66.39 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 112.995 0.739 . . . . 1.63 112.995 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -72.89 -22.47 60.75 Favored 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 112.72 0.637 . . . . 0.86 112.72 179.329 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.8 mt -71.95 -33.89 68.56 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 112.761 0.652 . . . . 1.57 112.761 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -174.43 40.74 0.13 Allowed Glycine 0 C--N 1.353 1.486 0 CA-C-O 119.62 -0.544 . . . . 1.79 113.79 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -102.79 58.45 0.56 Allowed Glycine 0 C--N 1.354 1.531 0 N-CA-C 111.43 -0.668 . . . . 2.85 111.43 179.091 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.3 ttpp 67.39 149.74 0.06 Allowed 'General case' 0 N--CA 1.483 1.188 0 C-N-CA 124.124 0.97 . . . . 6.7 111.977 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.48 1.026 0 CA-C-O 118.11 -0.948 . . . . 7.01 111.107 -179.896 . . . . . . . . 1 1 . 1 stop_ save_